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bstract
Due to the AIDS crisis, development of new, selective and safe non-nucleoside reverse transcriptase inhibitors (NNRTIs) remains
 high priority for medical research. The discovery of potential lead compounds by analogue based design studies was accomplished
sing 3D-QSAR and pharmacophore modelling of non-nucleoside reverse transcriptase inhibitors. A series of 24 diarylaniline
nalogues as NNRTIs were used to develop an atom based pharmacophore model. A five-point pharmacophore with two hydrogen
ond acceptors (A), one donor (D) and two aromatic rings (R) as pharmacophore features was selected and exhibited a statistically
ignificant correlation coefficient of R2 = 0.90 for the training set compounds and Q2 = 0.81 for a randomly chosen test set of
ompounds. The derived pharmacophore was used as a template to screen a specs database. The retrieved hits were progressively
assed through filters, such as the predicted activity, fitness score, Lipinski screen and docking scores. The surviving 12 hits
xhibited new scaffold (i.e., 2,4-dihydropyrano[2,3-c]pyrazole) for anti-HIV-1 chemotherapy as non-nucleoside reverse transcriptase
nhibitors.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Taibah University. This is an open access article under
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Acquired immunodeficiency syndrome (AIDS) is a
leading cause of death worldwide. Human immunode-
ficiency virus (HIV) is a retrovirus that can lead to
AIDS, which is a condition in humans where the immune
system begins to fail, leading to life-threatening oppor-
tunistic infections resulting in progressive destruction of
+behalf of Taibah University. This is an open access article under the
CD4 T lymphocytes and inexorable collapse of immune
function. The treatment with antiretrovirals may increase
the life expectancy of infected individuals [1,2]. HIV-1
is a retrovirus that encodes a reverse transcriptase (RT)
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required for viral replication [3]. RT is a key enzyme
that plays an essential and multifunctional role in the
replication of HIV-1 and considered to be an attractive
target for inhibition of HIV replication [4]. HIV-1 RT
catalyses the conversion of single-stranded RNA into
double-stranded DNA that is integrated into the host
cell’s genome [5]. Blocking each of the RT activities
can protect target cells from infection by HIV-1 [6]. Non-
nucleoside reverse transcriptase inhibitors (NNRTIs) are
key components of most current combination therapies
used to fight HIV-1 infections [7,8]. NNRTIs consist of a
variety of hydrophobic compounds that are potent non-
competitive inhibitors of the DNA polymerase activity
of HIV-1 RT. Most NNRTIs are highly specific against
HIV-1 RT, and, therefore, they are typically non-toxic
to human cells [6]. NNRTIs are highly lipophilic com-
pounds that are able to enter intact HIV-1 virions [9].
NNRTIs are a family of selective chemically diverse RT
targeting agents [10]. In anti-AIDS agent research, NNR-
TIs have gained a definitive and important position due
to their unique mechanism of action, antiviral potency,
high specificity, low toxicity and favourable pharmacoki-
netic properties [11,12]. Crystallographic studies have
shown that all of the NNRTIs bind in a transitory man-
ner to an allosteric hydrophobic binding pocket (the
non-nucleotide binding site, NNBS), which is located at
approximately 10 A˚ from the polymerase active site in
the p66 subunit causing reversible viral inactivation. The
formation of the RT-NNRTI complex results in short- and
long-range conformational changes that lock the enzyme
into an inactive form by affecting the geometry of the
polymerase active site aspartyl residues [10,13].
To date, more than 30 different classes of NNRTIs
have been reported. Among these classes, three com-
pounds (i.e., nevirapine, delavirdine and efavirenz) have
been approved by the food and drug administration
(FDA) for treatment of HIV-1 infected adults in com-
bination with nucleoside and protease analogues [4,11].
The development of new and more potent mutation-
resistant NNRTIs remains a challenging task for the
treatment of HIV-1 infected patients due to the drug
compliance, adverse effects and cross-resistance [14].
Diarylaniline analogues that are structurally related to
etravirine, riplivirine and TMC 120, which is a prior clin-
ical candidate, belong to the diarylpyrimidine (DAPY)
family, and all of these analogues are very potent against
wild-type and many drug-resistant HIV-1 strains with
nanomolar EC50 values. Diarylaniline analogues have
attracted considerable attention due to their excellent
activity and led to the identification of highly potent com-
pounds against both wild type and HIV-1 RT resistant
viral strains [15,16].versity for Science 9 (2015) 521–530
Currently, computational chemistry is the most
important contributor to rational drug design. Molecu-
lar modelling studies are an approach used to narrow
down a chemical library containing a large number of
molecules into a smaller list of potentially effective
inhibitors [17–19]. The quantitative structure–activity
relationship (QSAR) approach is very useful for the
prediction of biological activities, especially in drug
design. This approach is based on the assumption that
variations in the properties of the compounds can be cor-
related with changes in their molecular characteristics
[20]. A good QSAR model both enhances our under-
standing of the specifics of drug action and provides a
theoretical foundation for lead optimisation [19]. The
main purpose of quantitative structure–activity relation-
ship (QSAR) analyses is to make activity predictions
for unknown compounds to guide the structure-based
design of new analogues [21]. QSAR methodologies
save resources and expedite the development process
of new molecules and drugs [18,22,23]. The pharma-
cophore model development approach can be used to
correlate the observed biological activities for a series
of compounds with their chemical structures. The phar-
macophore model is widely employed to quantitatively
explore common chemical characteristics among a con-
siderable number of structures with great diversity. Such
a model could also be used as a query for screening
chemical databases to discover new chemical entities
[19,22]. By using 3D-QSAR models, the number of
compounds that need to be synthesised by a medici-
nal chemist can be substantially reduced. Therefore, the
time and cost of drug discovery and development can
also be reduced [18,19,22,24]. Docking is one method
where the binding of an inhibitor to a receptor can be
explored. Molecular docking is used to study how a
ligand interacts with its biological target and to con-
firm the conclusions of QSAR studies. Therefore, the
QSAR and docking techniques are valuable molecular
modelling tools for drug design [17–19,23,25]. The use
of ligand-based computer-aided molecular modelling
techniques to investigate the non-nucleoside inhibitor
binding pocket (NNIBP) of the RT enzyme has been
documented. The breadth of coverage encompasses
3D-QSAR pharmacophore based virtual screening and
docking studies [26]. The RT enzyme presents an
interesting target for computer-aided modelling studies
because the NNIBP is known to be flexible to accom-
modate inhibitors and change shapes depending on the
bound inhibitors. Virtual screening (VS) is a compu-
tational tool for biological screening to help medicinal
chemists filter out inactive molecules from a library of
compounds prior to synthesis.
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Table 1
Structure and biological activities of diarylaniline analogues against
HIV-1 IIIB wild-type virus.
NHO
R1R3
R2 R4
Comp. R1 R2 R3 R4 EC50 (M)
1 OMe NO2 H NO2 3.840
2 OMe NO2 Me NO2 2.990
3 OMe NO2 Br NO2 3.630
4 Me NO2 Br NO2 4.310
5 CN NO2 Br NO2 0.172
6 CN NO2 H NO2 0.545
7 CN NO2 CN NO2 4.190
8 CN NO2 Me NO2 0.280
9 CN NO2 CHO NO2 1.530
10 CN H Br NO2 0.317
11 CN H H NO2 3.147
12 CN H CN NO2 0.208
13 CN H Me NO2 0.067
14 CN H CHO NO2 2.190
15 CN H Br NH2 0.047
16 CN H CN NH2 0.070
17 CN H Me NH2 0.073
18 CN NH2 Br NH2 0.161
19 CN NH2 H NH2 3.226
20 CN NH2 CN NH2 0.030
21 CN NH2 Me NH2 0.070
22 CN NO2 Br NH2 0.016
23 CN NO2 CN NH2 0.003K.S. Bhadoriya et al. / Journal of Taib
.  Materials  and  methods
.1.  Software  and  hardware
The pharmacophore modelling and 3D-QSAR studies
ere carried out using PHASE version 3.0 as imple-
ented in the Maestro 8.5 modelling package from
chrodinger, Molecular Modelling Interface Inc., LLC,
ew York, USA installed on a Pentium IV 3.06 GHz,
ore 2 Duo Quad PC with Windows vista operating
ystem [27].
.2.  Data  set
A dataset consisting of 24 diarylaniline analogues
s anti HIV-1 was selected for the current study. The
hemical structures and EC50 values for the complete
et of compounds are listed in Table 1. The structures
f the compounds were sketched using the 2D struc-
ure draw application and converted to 3D structures. All
f the structures were minimised and optimised using
he OPLS 2005 force field with the LigPrep module.
onformers for each optimised structure were generated
sing ConfGen be applying the OPLS-2005 force field
ethod, and the lowest energy conformer was selected
or further study.
.3.  Pharmacophore  model  generation  and
alidation
PHASE is a versatile product for pharmacophore per-
eption, structural alignment, activity prediction, and 3D
atabase creation and searching. Given a set of molecules
ith an affinity for a particular target, PHASE utilises
ne-grained conformational sampling and a range of
coring techniques to identify a common pharmacophore
ypothesis, which conveys characteristics of the 3D
hemical structures that are reported to be critical for
inding. Each hypothesis is accompanied by a set of
ligned conformations that suggest the relative man-
er in which the molecules are likely to bind to the
eceptor [28]. A pharmacophore from all of the confor-
ations of the ligand in the active site was examined,
nd the pharmacophore that contain identical sets of
eatures with very similar spatial arrangements were
rouped together. Common pharmacophores were iden-
ified using a tree-based partitioning technique that
roups similar pharmacophores according to their inter-
ite distances (i.e., the distances between pairs of sites
n the pharmacophore). After applying default feature
efinitions to each ligand, common pharmacophores
ontaining five sites were generated using a terminal24 CN NO2 Me NH2 0.062
box size of 1 A˚ where all of the active molecules should
match.
2.4.  3D-QSAR
For 3D-QSAR studies, the total set of diarylaniline
analogues was randomly divided into a training set (18
compounds) for generation of 3D-QSAR models and a
test set (6 compounds) for validation of the developed
model (Table 2). For QSAR development, models of
the pharmacophore features of the training set molecules
were placed into a regular grid of cubes where each cube
allotted zero or more “bits” to account for the different
types of pharmacophore features in the training set that
occupy the cube (1 A˚). This representation gives rise to
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Table 2
Actual and predicted activity of QSAR dataset.
Ligand
name
Activity
(pEC50)
Predicted
activity
(pEC50)
Fitness QSAR Set
1 5.42 5.91 1.42 Training
2 5.52 5.31 1.43 Training
3 5.44 5.31 1.43 Test
4 5.37 5.31 1.43 Training
5 6.76 6.88 1.42 Training
6 6.26 6.11 1.48 Training
7 5.38 5.85 1.62 Training
8 6.55 6.27 1.46 Training
9 5.82 5.75 1.49 Test
10 6.50 6.48 1.51 Training
11 5.50 6.03 2.51 Training
12 6.68 6.25 1.53 Test
13 7.17 7.23 1.85 Training
14 5.66 5.96 1.88 Training
15 7.33 7.13 2.04 Training
16 7.16 7.45 1.81 Training
17 7.14 6.27 3 Training
18 6.79 7.07 1.91 Training
19 5.49 5.22 0.96 Training
20 7.52 7.19 1.63 Test
21 7.16 6.62 1.27 Test
22 7.80 7.36 1.72 Training
23 8.52 6.34 1.5 Test
24 7.21 7.18 1.34 Training
Fig. 1. The best common pharmacophore hypotheses (AADRR). Phar-
macophore features are red sphere for hydrogen bond acceptors (A)
blue sphere for hydrogen bond donor with the arrows pointing in the
Fig. 2. Relative intramolecular angle (a) and ddirection of lone pair and orange ring for aromatic rings (R). Blue cube
is for positive coefficient which indicates the increase in activity and
red cube is for negative coefficient contributes decrease in activity.
binary-valued occupation patterns that can be used as
independent variables to create 3D-QSAR models with
partial least-squares (PLS) factors. Statistics for the cor-
relation of the predicted activity with the actual activity
were collated for the hypothesis. Atom-based QSAR
models were generated for the hypothesis using the train-
ing set and contained one to five PLS factors, and the
models were validated by predicting the activity of the
test set of ligands. Fig. 1 shows the best pharmacophore
model features containing two acceptors, one donor and
two aromatic rings. Fig. 2 shows the relative distance
and angle between the pharmacophoric features.
istance (b) in pharmacophore model.
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Table 3
Statistical summary of the atom-based QSAR models with PHASE.
S. no. ID SD R2 F RMSE Q2 Pearson-R
1 AADRR.60 0.26 0.92 51.7 0.64 0.61 0.83
2 AADRR.57 0.29 0.90 42.1 0.57 0.69 0.90
3 ADHRR.26 0.45 0.75 14 0.63 0.63 0.85
Bold values indicate selected hypothesis for the QSAR studies.
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m.5.  Virtual  screening  and  docking  study
The derived pharmacophore model was used as a
uery for the exploration of novel scaffolds with poten-
ial anti-HIV-1 activity, in silico screening of 500,000
ompounds was performed from the Specs database.
he database query returned over 5000 hits matching
he pharmacophore hypothesis. These hits were filtered
y the different steps including the pharmacophore fit-
ess, predicted activity and Lipinski screening. The final
ompounds were subjected to HTVS (high through-
ut virtual screening) docking screening on HIV-1 RT
nzyme (PDB: 1S6Q). High scoring compounds were
elected for the SP docking analysis. As a second step,
nly compounds with GlideScore > 5.00 walked over
ere selected for a second run of docking in the XP
ode.
Fig. 3. Plots of predicted vs actual pEC503.  Results  and  discussion
3.1.  Common  pharmacophore  hypotheses
development
Common pharmacophore hypotheses were generated
by systematic variation of the number of sites (nsites) and
the number of matching active compounds (nact). With
nact = nact tot initially (nact tot is the total number of active
compounds in the training set), nsites decreased starting
from 7 until at least one hypothesis was found and scored
successfully. Common pharmacophores were examined
by a scoring protocol to identify the pharmacophore
from each surviving n-dimensional box that yields the
best alignment of the active set ligands. The scoring
protocol provides a ranking of different hypotheses to
choose the most appropriate one for further investigation.
for training (a) and test (b) sets.
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Table 4
Docking score and predicted activity of screened hits.
Ligand GScore LipophilicEvdW HBond Electro Predicted activity
Molecule 8458 −12.46 −6.61 −0.7 −0.32 5.8164
Molecule 8470 −12.42 −6.68 −0.7 −0.24 6.4506
Molecule 8454 −12.39 −6.87 −0.7 −0.35 6.4647
Molecule 8459 −11.72 −5.93 −0.74 −0.3 6.4767
Molecule 8471 −11.7 −5.92 −0.7 −0.28 6.5138
Molecule 8487 −11.69 −6.2 −0.7 −0.23 6.4945
Molecule 8488 −11.62 −6.14 −0.75 −0.1 6.6290
Molecule 8463 −11.54 −5.78 −0.75 −0.14 6.4638
Molecule 6638 −11.48 −5.88 −0.85 −0.37 5.9104
Molecule 11016 −11.16 −6.09 −0.7 −0.24 6.0100
Molecule 12487 −11.03 −5.41 −1.18 −0.35 5.4852
Molecule 13105 −10.99 −6.07 −1.12 −0.21 6.3400
Etravirine −8.87 −5.58 −0.59 −0.19 –
were screened out after pharmacophore based virtual
screening. These hits were further subjected to docking
screening.Navirapine −8.77 −4.66 
Riplivirine −8.52 −5.84 
Thirty-six five-point hypotheses survived to the three dif-
ferent phases of the PHASE scoring procedure (Survival,
Surv-inactive, Post hoc), and therefore, these hypotheses
were used for the generation of QSAR models.
3.2.  Analysis  and  validation  of  the  3D-QSAR  model
PHASE QSAR models may be either atom-based
or pharmacophore-based models, and the difference
between these models is whether all of the atoms are
taken into account or only the pharmacophore sites that
match the hypothesis. The choice of which type of model
to create depends largely on whether the training set
molecules are sufficiently rigid and congeneric. When
the structures contain a relatively small number of rotat-
able bonds and some common structural framework, an
atom-based model may work quite well. Our dataset
is congeneric. Therefore, we developed an atom-based
QSAR model using 18 training set compounds, and the
model was validated by predicting the activity of the test
set of ligands. The best pharmacophore model resulted in
AADRR.57 (R2 = 0.90) (Table 3). The goodness of the
model was validated by Q2 = 0.69 for the test set. The
plots of the predicted vs actual pEC50 for the training
and test sets are shown in Fig. 3.
3.3.  In  silico  screening  and  docking  studies
Pharmacophore based virtual screening of small-
molecule libraries is one aspect of a sophisticated
approach to drug discovery. For the exploration of novel
scaffolds with potential anti HIV-1 activity, in silico
screening of the specs database (www.specs.net), which
consists of 500,000 compounds was performed using−0.7 −0.24 –
−0.64 −0.18 –
the derived pharmacophore model, which represents the
essential 3D arrangement of functional groups com-
mon to a set of molecules. Hypothesis AADRR.57 was
used to screen the database, and a total of 5883 hitsFig. 4. In silico screening funnel.
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To investigate the detailed intermolecular interac-
ions between the ligand and the target enzyme/protein,
n automated docking programme (i.e., Glide) was
mployed. These studies helped to sort out the screened
ompounds. Three-dimensional structural information
n the target enzyme was obtained from PDB entry
S6Q, which has a resolution of 3.0 A˚. The processing
f the protein included the deletion of the ligand and
he solvent molecules as well as the addition of hydro-
en atoms. All 5883 hits were docked using Glide
TVS docking as implemented in the Maestro 9.0
oftware. The hits were sorted based on the docking
core to furnish only those hits that significantly inter-
cted with HIV-1 RT. The evaluation was performed
ith a glide score (docking score), and a single best
ose is generated as the output for a particular lig-
nd. The 176 qualified hits were subjected to Glide
P Docking for the 65 molecules sorted by dock-
ng score, which were subjected to Glide XP dockingeened hits.
(Fig. 4). 25 structurally varied hits were screened by XP
GlideScore & predicted activity. On visual observation,
12 hits exhibited a compelling pharmacophoric fea-
ture (AADRR) due to structural similarity with the
same basic 2,4-dihydropyrano[2,3-c] pyrazole nucleus
(Fig. 5), which contains an aromatic substitution in the
4th position, an amino group in the 5th position and a
nitrile group in the 6th position of the pyran ring. The
docking interaction indicated that this nucleus has the
same feature as the diarylaniline analogues, which is
responsible for the anti-HIV-1 activity. The results in
Table 4 indicate that the screened compounds have good
docking scores and H-bonding with a key residue in the
target protein (Lys 101, Val 179) compare to standard
drugs, such as etavirinine, navairapine and riplivirine
(Fig. 6). The aromatic substitution at the pyrazole ring
on the new 2,4-dihydropyrano[2,3-c]pyrazole scaffold
plays a role in the pi–pi stacking interaction. On the com-
bine ligand as well as structured based screening new
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Fig. 6. Docking interaction of screened compound and target protein (PDB: 1S6Q). (A) Dotted yellow bond showing H-bond interaction with
binding site residue (B) hydrophobic interaction.
re baseFig. 7. Pharmacopho
scaffold 2,4-dihydropyrano[2,3-c]pyrazole is screened
from the specs database, which is validated via the pre-
dicted activity and docking results (Fig. 7) for anti-HIV-1
chemotherapy as non-nucleoside reverse transcriptase
inhibitors.
4.  Conclusions
To evaluate new, selective and safe leads with anti-
HIV-1 activity for improved anti-HIV-1 chemotherapy,
a 3D-QSAR based pharmacophore model was gener-
ated for ligand based virtual screening, and the screened
compound were further evaluated by being docked into
a biological target. Diarylaniline analogues as anti-HIV-
1 were used to develop a pharmacophore model, andd lead optimisation.
a five-point pharmacophore model with two hydrogen
bond acceptors (A) as well as one donor and two aro-
matic rings (R) as pharmacophore features were used
for further screening. After rational screening and opti-
misation, 12 hit molecules were identified with the same
scaffold as 2,4-dihydropyrano[2,3-c]pyrazole contain-
ing aromatic substitution at the 4th position, an amino
group at the 5th position and a nitrile group at the 6th
position of the pyran ring. This discovery of a potent and
selective lead (i.e., 2,4-dihydropyrano[2,3-c]pyrazole)
with anti-HIV-1 activity by 3D pharmacophore vir-
tual screening indicates the efficiency of this type
of approach for drug discovery, which is econom-
ical and saves a considerable amount of time and
labour.
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